| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/28/2007 | EP1756159A1 C1q family member proteins with altered immunogenicity |
| 02/28/2007 | EP1756158A1 Method for activating of t cell protein tyrosine phosphatase and therapeutical methods based thereon |
| 02/28/2007 | EP1756152A2 Biologically active peptide vapeehptllteaplnpk derivatives |
| 02/28/2007 | EP1756151A1 Osteoblast growth factor |
| 02/28/2007 | EP1756147A2 Peptides for inducing a ctl and/or htl response to hepatitis c virus |
| 02/28/2007 | EP1756142A1 Pseudopeptides growth hormone secretagogues |
| 02/28/2007 | EP1756039A2 Compounds and compositions for delivering active agents |
| 02/28/2007 | EP1755672A2 Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| 02/28/2007 | EP1755669A2 Methods and compositions for specifically targeting human hepatocellular carcinoma cells |
| 02/28/2007 | EP1755667A2 Stable peptide mimetic of hiv gp41 fusion intermediate |
| 02/28/2007 | EP1755665A2 Compositions and methods for mucosal vaccination |
| 02/28/2007 | EP1755661A2 Use of gelsolin to treat infections |
| 02/28/2007 | EP1755660A2 Method for enhancing or inhibiting insulin-like growth factor-i |
| 02/28/2007 | EP1755659A2 Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
| 02/28/2007 | EP1755658A2 Human complement c3 derivates with cobra venom factor-like function |
| 02/28/2007 | EP1755656A1 Enzymes for pharmaceutical use |
| 02/28/2007 | EP1755655A2 Methods and compositions for reducing oxalate concentrations |
| 02/28/2007 | EP1755654A2 Methods and systems for treatment of neurological diseases of the central nervous system |
| 02/28/2007 | EP1755653A2 Treatment methods utilizing albumin-binding proteins as targets |
| 02/28/2007 | EP1755652A1 Factor ixa for the treatment of bleeding disorders |
| 02/28/2007 | EP1755651A1 Cosmetic preparations containing pth fragments |
| 02/28/2007 | EP1755650A2 A biomolecule-containing formulation of increased stability |
| 02/28/2007 | EP1755649A1 Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6 |
| 02/28/2007 | EP1755648A2 Cerberus/coco derivatives and uses thereof |
| 02/28/2007 | EP1755647A1 Treatment of amyotrophic lateral sclerosis |
| 02/28/2007 | EP1755646A2 Vascular targets for detecting, imaging and treating neoplasia or neovasculature |
| 02/28/2007 | EP1755645A2 Vegf inhibitors for the treatment of malignant pleural effusion |
| 02/28/2007 | EP1755644A2 Compositions comprising addl receptor syngap |
| 02/28/2007 | EP1755643A2 Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells |
| 02/28/2007 | EP1755642A1 Annexin v for preventing atherothrombois and plaque rupture |
| 02/28/2007 | EP1755641A2 Agonists and antagonists of p28, ebi3 and wsx/tccr for treating immune disorders |
| 02/28/2007 | EP1755640A1 Hybrid recombinases for genome manipulation |
| 02/28/2007 | EP1755639A2 Epitopes related to coeliac disease |
| 02/28/2007 | EP1755638A1 Multiple agent therapy for sexual dysfunction |
| 02/28/2007 | EP1755637A1 Methods for preventing or treating bone disorders |
| 02/28/2007 | EP1755636A1 Sustained release composition |
| 02/28/2007 | EP1755635A1 Treatment of inflammatory airway disease |
| 02/28/2007 | EP1755634A1 Oligopeptides for reducing elevated blood urea concentration |
| 02/28/2007 | EP1755633A1 Oral delivery of peptide pharmaceutical compositions |
| 02/28/2007 | EP1755632A1 Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a gst-activated anticancer compound |
| 02/28/2007 | EP1755631A2 Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes |
| 02/28/2007 | EP1755622A1 Treatment with oxaliplatin and an egfr-inhibitor |
| 02/28/2007 | EP1755611A1 Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| 02/28/2007 | EP1755582A1 Pharmaceutical compositions for the prevention and treatment of atherosclerosis |
| 02/28/2007 | EP1755580A1 Use of alpha-ketoglutarate and related compounds for lowering plasma lipids |
| 02/28/2007 | EP1755391A2 Methods and compositions for treating neuropathies |
| 02/28/2007 | EP1689437B1 Erythropoietin solution formulation |
| 02/28/2007 | EP1662903B1 Food composition |
| 02/28/2007 | EP1633381A4 Assays using amyloid precursor proteins with modified beta-secretase cleavage sites to monitor beta-secretase activity |
| 02/28/2007 | EP1578778A4 Ghrelin analogs |
| 02/28/2007 | EP1551375B1 Pharmaceutical formulation comprising cyclosporin, propylene glycol ester and non-ionic surfactant |
| 02/28/2007 | EP1539803B1 Fluoro-alkyl-cyclopeptide derivatives having anti-integrin activity |
| 02/28/2007 | EP1531853B1 Synergistic combination of silk proteins |
| 02/28/2007 | EP1518117B1 Method for diagnosing and treating nis-expressing carcinomas and metastases |
| 02/28/2007 | EP1381397B1 Stabilisation of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman |
| 02/28/2007 | EP1346041B1 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease |
| 02/28/2007 | EP1337258A4 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof |
| 02/28/2007 | EP1320541B1 Tgf-beta inhibitors and methods |
| 02/28/2007 | EP1301201B1 Treatment of glycogen storage disease type ii |
| 02/28/2007 | EP1276491B9 Tamandarin and didemnin analogs and methods of making and using them |
| 02/28/2007 | EP1272186B1 Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 02/28/2007 | EP1265606B9 Cell adhesion inhibitors |
| 02/28/2007 | EP1257575B1 Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy |
| 02/28/2007 | EP1254240B1 Hybrid protease with reduced antigenicity and its use |
| 02/28/2007 | EP1250424B1 Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules |
| 02/28/2007 | EP1248848B1 Methods and materials relating to stem cell growth factor-like poypeptides and polynucleotides |
| 02/28/2007 | EP1204679B1 Peptides containing n-substituted d-amino acids for preventing beta-strand association |
| 02/28/2007 | EP1123313B1 Methods and compositions for the prevention and treatment of anemia |
| 02/28/2007 | EP1085811B1 Broad specificity dna damage endonuclease |
| 02/28/2007 | EP1083915B1 Compositions comprising molybdenum for enhancing protein anabolism and detoxification |
| 02/28/2007 | EP1077999B1 Moraxella catharralis proteins |
| 02/28/2007 | EP1073737B1 Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction) |
| 02/28/2007 | EP1067879B1 Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation |
| 02/28/2007 | EP1029035B1 Method for inducing osteoblast differentiation of human extramedullary adipose tissue cells |
| 02/28/2007 | EP0945506B1 Proteine avec une activite de suppression du vieillissement |
| 02/28/2007 | EP0938497B1 Constrained helical peptides and methods of making same |
| 02/28/2007 | EP0909323B1 Helicobacter pylori bacterioferritin |
| 02/28/2007 | EP0888122B1 HYBRID WITH INTERFERON-alpha AND AN IMMUNOGLOBULIN Fc LINKED THROUGH A NON-IMMUNOGENIC PEPTIDE |
| 02/28/2007 | EP0833840B1 Hypoxia inducible factor-1 and method of use |
| 02/28/2007 | EP0759083B1 Methods of inducing gene expression by ionizing radiation |
| 02/28/2007 | EP0758390B1 Angiostatin and method of use for inhibition of angiogenesis |
| 02/28/2007 | EP0726948B1 Method of inducing and maintaining neuronal cells |
| 02/28/2007 | CN1922332A Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
| 02/28/2007 | CN1922324A Bacterial virulence factors and uses thereof |
| 02/28/2007 | CN1922314A Fungall cell wall degrading enzyme |
| 02/28/2007 | CN1922313A Acid alpha-glucosidase and fragments thereof |
| 02/28/2007 | CN1922309A A respiratory syncytial virus with a genomic deficiency complemented in trans |
| 02/28/2007 | CN1922208A Methods and compositions for inhibiting c-met dimerization and activation |
| 02/28/2007 | CN1922206A Process for the preparation of latent antithrombin iii |
| 02/28/2007 | CN1922137A Protease inhibitors |
| 02/28/2007 | CN1921896A Haemostatic sprays and compositions |
| 02/28/2007 | CN1921886A Methods of modulating cytokine activity, related reagents |
| 02/28/2007 | CN1921881A Use of hydroxylated amino acids for treating diabetes |
| 02/28/2007 | CN1921880A Protein drug sustained-release microparticle preparation for injection and process for producing the same |
| 02/28/2007 | CN1921879A Means for stimulation and activation of hair growth by il-15 |
| 02/28/2007 | CN1921878A Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients |
| 02/28/2007 | CN1921877A Charperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion |
| 02/28/2007 | CN1921876A Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug |
| 02/28/2007 | CN1920049A Small molecule bioactive peptide, preparation method, composition and application thereof |
| 02/28/2007 | CN1920014A Phosphokinase PKD2 and application thereof |